Analysts’ Recent Ratings Updates for Opus Genetics (IRD)

Opus Genetics (NASDAQ: IRD) has recently received a number of price target changes and ratings updates:

• 12/13/2025 – Opus Genetics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/10/2025 – Opus Genetics is now covered by analysts at B. Riley. They set a “buy” rating and a $9.00 price target on the stock.
• 12/1/2025 – Opus Genetics was upgraded by analysts at Brookline Capital Management to a “strong-buy” rating.
• 11/25/2025 – Opus Genetics is now covered by analysts at Piper Sandler. They set an “overweight” rating and a $7.00 price target on the stock.
• 11/25/2025 – Opus Genetics is now covered by analysts at Piper Sandler. They set an “overweight” rating and a $7.00 price target on the stock.
• 11/15/2025 – Opus Genetics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/13/2025 – Opus Genetics had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $9.00 price target on the stock.
• 11/7/2025 – Opus Genetics had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $9.00 price target on the stock.
• 10/29/2025 – Opus Genetics is now covered by analysts at Wedbush. They set an “outperform” rating and a $8.00 price target on the stock.

Insider Buying and Selling at Opus Genetics

In other news, Director Fighting Blindness Foundation sold 4,000,000 shares of Opus Genetics stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $2.15, for a total value of $8,600,000.00. Following the completion of the sale, the director directly owned 5,492,171 shares of the company’s stock, valued at approximately $11,808,167.65. The trade was a 42.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 6.60% of the company’s stock.

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.